Reset filter
Nyckelord
Parkinson Disease ×
Visa mer Nyckelord
Innehållsförteckning
  1. 1. Clinical Trial
  2. 2. Routine Documentation
  3. 3. Registry/Cohort Study
  4. 4. Quality Assurance
  5. 5. Data Standard
  6. 6. Patient-Reported Outcome
  7. 7. Medical Specialty
    1. 7.1. Anesthesiology
    1. 7.2. Dermatology
    1. 7.3. ENT
    1. 7.4. Geriatrics
    1. 7.5. Gynecology/Obstetrics
    1. 7.6. Internal Medicine
      1. Hematology
      1. Infectious Diseases
      1. Cardiology/Angiology
      1. Pneumology
      1. Gastroenterology
      1. Nephrology
      1. Endocrinology/Metabolic Diseases
      1. Rheumatology
    1. 7.7. Neurology
    1. 7.8. Ophthalmology
    1. 7.9. Palliative Care
    1. 7.10. Pathology/Forensics
    1. 7.11. Pediatrics
    1. 7.12. Psychiatry/Psychosomatics
    1. 7.13. Radiology
    1. 7.14. Surgery
      1. General/Visceral Surgery
      1. Neurosurgery
      1. Plastic Surgery
      1. Thoracic Surgery
      1. Trauma/Orthopedics
      1. Vascular Surgery
    1. 7.15. Urology
    1. 7.16. Dental Medicine/OMS
Valda datamodeller

Du måste vara inloggad för att välja flera datamodeller, ladda ner dem eller analysera dem.

191 Sökresultat.
Relevans Bedömning Nya först Gamla först

L-dopa controlled study of ropinirole, neuroprotective effect and ophthalmological safety in early Parkinson’s disease 101468/125 Module 2 Visit 5 Month 3

- 10/24/17 - 1 Formulär, 13 Item-grupper, 52 Dataelement, 1 Språk
Item-grupper: General information, Flexible Dose Start Date and Current Dose Level, Vital signs, Concomitant Medication, Adverse Experiences, Study Medication Compliance, Concomitant medication, Details of Concomitant Medication, Levodopa rescue, Details of Ledopa Rescue Therapy, Adverse Experiences, Details on adverse experiences, Patient Continuation/Withdrawal
Study ID: 101468/125 Clinical Study ID: SKF-101468/125 Study Title: A double-blind, multicentre, flexible dose, L-dopa controlled study of ropinirole to investigate A) neuroprotective effect as measured by 3D PET scanning, and B) ophthalmological safety, in patients with early Parkinson’s disease Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: Sponsor: GlaxoSmithKline Collaborators: N/A Phase: phase 3 Study Recruitment Status: Completed Generic Name: ropinirole Trade Name: requip Study Indication: Restless Legs Syndrome

Eligibility Parkinson's Disease NCT01636011

- 1/13/19 - 1 Formulär, 2 Item-grupper, 9 Dataelement, 1 Språk
Item-grupper: Inclusion Criteria, Exclusion Criteria
Effect of Osteopathic Manipulative Medicine (OMM) on Pulmonary Function and Speech in Parkinson's Disease; ODM derived from: https://clinicaltrials.gov/show/NCT01636011

Eligibility Parkinson's Disease NCT00892450

- 9/20/21 - 1 Formulär, 2 Item-grupper, 20 Dataelement, 1 Språk
Item-grupper: Inclusion Criteria, Exclusion Criteria
Anticholinergic Therapy for Overactive Bladder in Parkinson's Disease; ODM derived from: https://clinicaltrials.gov/show/NCT00892450

Eligibility Parkinson's Disease NCT02415062

- 6/8/19 - 1 Formulär, 1 Item-grupp, 18 Dataelement, 1 Språk
Item-grupp: Criteria
The Efficacy and Safety Study of High Dose Donepezil in Parkinson's Disease With Dementia; ODM derived from: https://clinicaltrials.gov/show/NCT02415062

Eligibility Parkinson's Disease NCT00917280

- 8/24/18 - 1 Formulär, 1 Item-grupp, 16 Dataelement, 1 Språk
Item-grupp: Criteria
Connecting the Lab to Everyday Life: The Relevance of Executive Dysfunction to Participation and Quality of Life in Parkinson's Disease (PD) Without Dementia; ODM derived from: https://clinicaltrials.gov/show/NCT00917280

Eligibility Parkinson's Disease NCT02302521

- 6/8/19 - 1 Formulär, 2 Item-grupper, 16 Dataelement, 1 Språk
Item-grupper: Inclusion Criteria, Exclusion Criteria
Motion Immune Magnetic Resonance Imaging (MRI); ODM derived from: https://clinicaltrials.gov/show/NCT02302521

dbGaP phs001004 Genetic Analysis of Parkinson's Disease - Eligibility

- 9/19/23 - 6 Formulär, 1 Item-grupp, 1 Dataelement, 1 Språk
Item-grupp: IG.elig
Principal Investigator: Tatiana Foroud, PhD, Indiana University, IN, USA MeSH: Parkinson Disease https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs001004 A portion of the sample includes multiplex PD families recruited as part of a previously funded study (R01NS037167; PI: Tatiana Foroud). Families were ascertained initially through a living affected sibling pair. Subsequently, ascertainment was loosened to include PD probands having a positive family history of PD in a first degree relative, who was not required to be part of the study. All individuals completed an in-person evaluation at one of the 65 Parkinson Study Group sites participating in this study. Individuals completed a detailed evaluation that included the Unified Parkinson Disease Rating Scale (UPDRS), Mini-Mental State Examination (MMSE), Geriatric Depression Scale (GDS) and a diagnostic checklist that implemented the UK PD Brain Bank inclusion and exclusion criteria. An autopsy program was established in this study and brain tissue for confirmation of diagnosis and further experimental study are available from over 100 participants. Autopsy confirmation of the PD diagnosis was nearly 100% for those who met UK PD Brain Bank criteria. In addition, because this was a cross sectional study and family members were often seen very early in disease course, among those who did not meet UK PD Brain Bank criteria but had a subsequent autopsy, a significant subset (1/3) had autopsy confirmation of PD. The second source of samples is from the NINDS Human Genetics DNA and Cell Line Repository located at the Coriell Institute. Currently DNA from 4,509 PD patients is available from the Coriell Institute. We restricted the selected sample to include only Caucasians and ensured there was no overlap with samples contributed by the PROGENI Study.

pht010439.v1.p1

1 Item-grupp 5 Dataelement

pht010440.v1.p1

1 Item-grupp 5 Dataelement

pht010441.v1.p1

1 Item-grupp 3 Dataelement

pht010442.v1.p1

1 Item-grupp 37 Dataelement

pht010443.v1.p1

1 Item-grupp 3 Dataelement

Eligibility Parkinson's Disease NCT00639275

- 8/21/18 - 1 Formulär, 2 Item-grupper, 18 Dataelement, 1 Språk
Item-grupper: Inclusion Criteria, Exclusion Criteria
Deep Brain Stimulation and Digestive Symptomatology; ODM derived from: https://clinicaltrials.gov/show/NCT00639275

Eligibility Parkinson's Disease NCT00855621

- 8/22/18 - 1 Formulär, 2 Item-grupper, 15 Dataelement, 1 Språk
Item-grupper: Inclusion Criteria, Exclusion Criteria
Effects of Deep Brain Stimulation in Parkinson's Disease; ODM derived from: https://clinicaltrials.gov/show/NCT00855621

Eligibility Parkinson's Disease NCT02046434

- 6/7/19 - 1 Formulär, 2 Item-grupper, 10 Dataelement, 1 Språk
Item-grupper: Inclusion Criteria, Exclusion Criteria
Phenylbutyrate Response as a Biomarker for Alpha-synuclein Clearance From the Brain; ODM derived from: https://clinicaltrials.gov/show/NCT02046434

Eligibility Parkinson Disease NCT02402569

- 6/6/19 - 1 Formulär, 2 Item-grupper, 16 Dataelement, 1 Språk
Item-grupper: Inclusion Criteria, Exclusion Criteria
Multi-electrodes Set for Deep Brain Stimulation in Parkinson Disease; ODM derived from: https://clinicaltrials.gov/show/NCT02402569

Eligibility Idiopathic Parkinson's Disease NCT00663312

- 5/6/18 - 1 Formulär, 1 Item-grupp, 17 Dataelement, 1 Språk
Item-grupp: Criteria
Impact of Deep Brain Stimulation of Subthalamic Nucleus on the Hepatic Glucose Production in Parkinson's Disease; ODM derived from: https://clinicaltrials.gov/show/NCT00663312

Kontakt

Använd detta formulär för feedback, frågor och förslag på förbättringar.

Fält markerade med * är obligatoriska.

Hjälp

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial